Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 7/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | REN | P00797 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PEPD | P12955 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.39 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674102 | 1.00 | CYP1A2 (0.41) | CYP1A2ACECYP2C19RENLMNA | |
| SCHEMBL6516948 | 1.00 | CYP1A2 (0.41) | CYP1A2ACECYP2C19RENLMNA | |
| SCHEMBL13545424 | 0.94 | SMN1; SMN2 (0.43) | CYP1A2ACECYP2C19LMNASLC6A1 | |
| SCHEMBL9090390 | 0.89 | ACE (0.41) | CYP1A2ACECYP2C19RENLMNA | |
| SCHEMBL9090397 | 0.89 | ACE (0.41) | CYP1A2ACECYP2C19RENLMNA | |
| SCHEMBL1645702 | 0.86 | ACE (0.39) | CYP1A2ACECYP2C19 | |
| SCHEMBL17052427 | 0.84 | ACE (0.43) | CYP1A2ACECYP2C19RENLMNA | |
| SCHEMBL28452245 | 0.84 | ACE (0.43) | CYP1A2ACECYP2C19RENLMNA | |
| SCHEMBL25030103 | 0.83 | SLC6A9 (0.40) | CYP1A2CYP2C19LTA4HSMN1; SMN2RAB9A | |
| SCHEMBL25030104 | 0.83 | SLC6A9 (0.40) | CYP1A2CYP2C19LTA4HSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117001-A1 | FLUOROPHORE-POLYMER CONJUGATES AND USES THEREOF | ERISYON INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2024076928-A1 | FLUOROPHORE-POLYMER CONJUGATES AND USES THEREOF | ERISYON INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| EP-2291390-B1 | NEW OPTICALLY PURE COMPOUNDS FOR IMPROVED THERAPEUTIC EFFICIENCY | CENTRE NAT RECH SCIENT (FR) | 2014-11-05 | — | — | EP | disclosed |
| EP-1513871-B1 | PYRROLIDINYL PEPTIDE NUCLEIC ACIDS | ISIS INNOVATION (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-7098321-B2 | Homologous peptide nucleic acids | ISIS INNOVATION LIMITED (GB) | 2006-08-29 | — | — | US | disclosed |
| EP-1513871-A2 | PYRROLIDINYL PEPTIDE NUCLEIC ACIDS | Isis Innovation Limited (GB) | 2005-03-16 | — | — | EP | disclosed |
| US-6716961-B2 | Chiral peptide nucleic acids with a N-aminoethyl-d-proline backbone | ISIS INNOVATION LIMITED (GB) | 2004-04-06 | — | — | US | disclosed |
| US-6716961-B2 | Chiral peptide nucleic acids with a N-aminoethyl-d-proline backbone | ISIS INNOVATION LIMITED (GB) | 2004-04-06 | — | — | US | disclosed |
| US-20030228588-A1 | Homologous peptide nucleic acids | ISIS INNOVATION LIMITED | 2003-12-11 | — | — | US | disclosed |
| US-20030162699-A1 | Chiral peptide nucleic acids with a n-aminoethyl-d-proline backbone | ISIS INNOVATION LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-20030162699-A1 | Chiral peptide nucleic acids with a n-aminoethyl-d-proline backbone | ISIS INNOVATION LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-20030157500-A1 | Pyrrolidinyl peptide nucleic acids | ISIS INNOVATION LIMITED (GB) | 2003-08-21 | — | — | US | disclosed |
| WO-2003066902-A2 | PYRROLIDINYL PEPTIDE NUCLEIC ACIDS | ISIS INNOVATION LIMITED (GB) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030157500-A1 | Pyrrolidinyl peptide nucleic acids | POLRMT, POLH, PCNA | CYP1A2 4697/4885ACE 3500/4885CYP2C19 4031/4885 |
| US-20030162699-A1 | Chiral peptide nucleic acids with a n-aminoethyl-d-proline backbone | POLL, HNRNPL, RNGTT | CYP1A2 4864/4885ACE 391/4885CYP2C19 4676/4885 |
| US-20030228588-A1 | Homologous peptide nucleic acids | HNRNPH3, PCNA, POLL | CYP1A2 4709/4885ACE 3394/4885CYP2C19 4302/4885 |
| US-20260117001-A1 | FLUOROPHORE-POLYMER CONJUGATES AND USES THEREOF | QPCTL, QRFPR, CD47 | CYP1A2 4788/4885ACE 3469/4885CYP2C19 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.